Rationale and results of correction of cognitive dysfunction in patients with chronic heart failure and a reduced left ventricular ejection fraction using a combination of meldonium and gamma-butyrobetaine
Journal Title: Серце і судини - Year 2018, Vol 0, Issue 4
Abstract
The aim — to evaluate the effect of the innovative combination of meltedonium and γ‑butyrobetaine (GBB) on the state of cognitive function, quality of life and endothelial function in patients with chronic heart failure (CHF) and reduced left ventricular ejection fraction (LV EF). Materials and methods. We examined 24 patients with stable CHF and reduced LV EF (< 40 %) of the II — III functional class according to NYHA not older than 75 years who had cognitive impairments identified using standardized testing. All patients underwent general clinical examination using standard methods of psychological testing (Mini‑Mental State Examination (MMSE), Schulte tests, HADS scale, Minnesota Living with Heart Failure Questionnaire (MLHFQ), self‑assessment by patients of household physical activity using the Duke University questionnaire), ultrasound diagnosis of the vasodilating function of the endothelium of the brachial artery (VDFE BA) using a test with reactive hyperemia. The combination of meldonium with GBB was administered in a dose of 2 capsules three times a day (every 8 hours) for 4 weeks. Results and discussion. After treatment with a combination of meldonium and GBB, we observed a statistically significant improvement in cognitive function indicators on the MMSE scale (p < 0.001), Schulte test (p < 0.001), as well as the quality of life by MLHFQ (p = 0.02). While taking the drug, a significant improvement of the endothelium‑dependent vasodilatory response was observed (p < 0.001). No statistically significant effect of the combination of meldonium and GBB on the level of anxiety (HADS‑A scale) and depression (HADS‑D) was observed. Conclusions. Administration to patients with CHF and decreased LV EF of a fixed combination of meldonium and GBB for 4 weeks in addition to standard basic treatment (angiotensin‑converting enzyme inhibitor, b‑blocker, mineralcorticoid receptor antagonist, diuretic) was associated with a statistically significant improvement in cognitive tests results (total score by MMSE, Schulte test run time), quality of life by MLHFQ and significant improvement in VDFE BA according to the test with reactive hyperemia.
Authors and Affiliations
L. G. Voronkov, A. S. Solonovych, A. V. Liashenko
Keywords
Related Articles
- EP ID EP451277
- DOI 10.30978/HV2018-4-62
- Views 137
- Downloads 0
Clinical and anamnestic characteristics of patients with acute pulmonary embolism
The aim — to analyze the features of the course and the main factors of development of pulmonary embolism (PE). Materials and methods. During the period from January 1, 2014 until July 1, 2018, 774 patients with acute p...
The advisability of carotid endarterectomy up to 48 — 72 hours after acute cerebrovascular impairment in patients with symptomatic internal carotid artery stenosis of more than 50 %
The aim — to evaluate the results of carotid endarterectomy (CEA) in the acute period of ischemic stroke. Materials and methods. The paper presents the results analysis of CEA performed in 260 patients with symptomatic i...
Methods of treating patients with non‑restructuring chronic critical lower limb ischemia using autologous mesenchymal stem cells
The prevalence of peripheral arteries disease (PAD) ranges from 3 to 10 % in the general population, reaching 15 — 20 % in subjects older than 70 years. PDA affects 27 million people in Europe and the USA. The annual num...
Age and gender differences in phenotype of heart failure with preserved left ventricular ejection fraction in patients with arterial hypertension
The aim — to determine differences in the structure and function of the heart, arterial stiffness, resistive and pulsative loads and ventricular‑arterial connection in patients with arterial hypertension, confirmed heart...
Experience of use of 2-ethyl-6-methyl-3-hydroxypyridine succinate in complex therapy of stable angina
The aim — to evaluate the efficacy and tolerability of the use of different doses (200 and 500 mg/day) of 2‑ethyl‑6‑methyl‑3‑hydroxypyridine succinate (Venokor, Lekhim, Ukraine) in the complex therapy of patients with co...